Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been assigned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $10.80.

Several equities analysts have recently weighed in on the stock. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th.

Hedge Funds Weigh In On Regulus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in RGLS. Creative Planning bought a new position in shares of Regulus Therapeutics in the third quarter valued at approximately $26,000. SG Americas Securities LLC bought a new position in Regulus Therapeutics during the 3rd quarter valued at $33,000. Jane Street Group LLC purchased a new position in Regulus Therapeutics during the 3rd quarter worth $46,000. Rhumbline Advisers bought a new stake in shares of Regulus Therapeutics in the 2nd quarter worth $136,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 52,059 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Stock Performance

Shares of RGLS stock opened at $1.41 on Friday. Regulus Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $3.79. The stock has a 50 day simple moving average of $1.54 and a two-hundred day simple moving average of $1.60. The company has a market cap of $92.36 million, a P/E ratio of -1.32 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, research analysts predict that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.